NSE: GLAND · 9 November 2026
- Gland Pharma Ltd. shares rose 5.41% today, finishing at ₹3,302.40 after moving within a wide intraday range of ₹3,140.80 and ₹3,374.00.
- Gland Pharma announced the appointment of Mr. Xiao Le as the Chief Investment Officer for its wholly-owned subsidiary, Gland Pharma International Pte. Ltd., effective November 09, 2026. Mr. Xiao Le brings over 15 years of experience in investment and asset management across medical devices, biopharma, and healthcare services, holding degrees from Johns Hopkins University and MIT. He will be responsible for exploring investment opportunities and improving M&A capabilities in the U.S., China, Singapore, and other regions.
- Trading volume was 6.86 times the 20-day average daily volume.
Why is Gland Pharma share price rising on 9 November 2026?
Gland Pharma Ltd. shares rose 5.41% today, finishing at ₹3,302.40 after moving within a wide intraday range of ₹3,140.80 and ₹3,374.00.
The broader pharmaceutical sector experienced positive momentum today, with the Nifty Pharma sector benchmark advancing 3.42%, while the broader Nifty inched up by 0.06%. Gland Pharma outperformed both the broader market and its sector benchmark, building upon a 5-day return of 7.69% and a 20-day return of 7.86%.
Company disclosures from recent days include the appointment of Mr. Xiao Le as Chief Investment Officer for Gland Pharma International Pte. Ltd., effective November 09, 2026, to oversee M&A and investment opportunities across the U.S., China, and Singapore. While this operational update provides context on ongoing management strengthening, its direct link to today's intraday price action remains part of broader corporate developments.
24.37 lakh shares traded by 9 November 2026 · 03:30 PM IST. This compares with a 20-day average daily volume of 3.55 lakh shares (6.86 times). The five-day average daily volume was 4.04 lakh shares. Separately, the NSE report for 9 November 2026 showed 5.60 lakh shares delivered, representing 22.98% of that day’s traded volume. The same report recorded 216,218 trades.
The stock's 5.41% gain aligns with strong outperformance within the Nifty Pharma sector, backed by heavy cash volume exceeding 6.86 times the 20-day average and ongoing positive sentiment following recent quarterly results and management expansions.
Latest Company Developments
Gland Pharma announced the appointment of Mr. Xiao Le as the Chief Investment Officer for its wholly-owned subsidiary, Gland Pharma International Pte. Ltd., effective November 09, 2026. Mr. Xiao Le brings over 15 years of experience in investment and asset management across medical devices, biopharma, and healthcare services, holding degrees from Johns Hopkins University and MIT. He will be responsible for exploring investment opportunities and improving M&A capabilities in the U.S., China, Singapore, and other regions.
Strengthens leadership for international expansion and strategic M&A initiatives in core overseas markets.
The company submitted the scrutinizer's report and voting results for its postal ballot that concluded on November 05, 2026. Shareholders approved the ordinary resolution for the appointment of Mr. Xingli Wang as a Non-Executive and Non-Independent Director with the requisite majority of 97.06% of total votes polled.
Formalizes board composition updates following remote e-voting participation by institutional and non-institutional members.
Gland Pharma reported its financial performance for the quarter ended September 30, 2026, posting a 23% year-on-year increase in revenue from operations to ₹18,336 million and a 58% growth in profit after tax to ₹2,908 million. The CDMO business grew 31% year-on-year to ₹8,227 million, while Critical Injectables expanded by 18% to ₹10,109 million.
Demonstrates robust operational execution and double-digit growth across key business verticals.
Appointment of Mr Xiao Le as the Chief Investment Officer for Gland Pharma International Pte. Ltd (Wholly- owned subsidiary of Gland Pharma Limited), effective November 09, 2026
Gland Pharma shares jump 4% as Q2 profit jumps 58%, revenue rises 23% YoY The Economic Times
Ownership & Transaction Activity
Mutual Fund Holdings
Mutual funds held 29.52% on 30 September 2026. This compares with 28.23% on 30 June 2026, a change of +1.29 percentage points.
The filing reported 31 MF/UTI holders.
Research & Brokerage Views
Upgraded the stock following strong quarterly financial performance and solid midcap positioning.
Historical Bulk / Block Deals
What to Watch Next
- Execution of technology transfer activities under the global CDMO partnership
- Progress on U.S. regulatory filings and commercialization of the 24 filed Ready-to-Use infusion bags
- Integration and performance of newly acquired step-down subsidiary Novelstar Pharma Inc.
- Sustained delivery volumes and cash market participation relative to the 20-day average
More Gland Pharma news and dated analysis →
Frequently Asked Questions
What is the latest Gland Pharma company news?
Gland Pharma announced the appointment of Mr. Xiao Le as the Chief Investment Officer for its wholly-owned subsidiary, Gland Pharma International Pte. Ltd., effective November 09, 2026. Mr. Xiao Le brings over 15 years of experience in investment and asset management across medical devices, biopharma, and healthcare services, holding degrees from Johns Hopkins University and MIT. He will be responsible for exploring investment opportunities and improving M&A capabilities in the U.S., China, Singapore, and other regions.
How strong was Gland Pharma’s trading volume?
24.37 lakh shares traded, 6.86 times the 20-day average daily volume. The price and volume data are dated 9 November 2026 · 03:30 PM IST.
Do the mutual-fund figures show buying today?
They show holdings on 30 September 2026. Quarterly holdings do not identify purchases made on the article date.
Research & analysis: WittyTrades Research Desk
Reviewed by: Mohanish Sanghavi — SEBI Registered Research Analyst
Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.